for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beximco Pharmaceuticals Limited

BXPq.L

Latest Trade

42.00GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

34.10

 - 

52.70

As of on the Dhaka Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
42.00
Open
--
Volume
--
3M AVG Volume
2.83
Today's High
--
Today's Low
--
52 Week High
52.70
52 Week Low
34.10
Shares Out (MIL)
405.56
Market Cap (MIL)
31,876.74
Forward P/E
--
Dividend (Yield %)
1.91

Next Event

Dividend For BXPq.L - 0.0177 USD

Latest Developments

More

Beximco Pharmaceuticals Ltd declares dividend

Beximco Pharmaceuticals Ltd recommends 10 pct cash dividend and 5 pct stock dividend

Beximco Pharmaceuticals Ltd enters into new loan agreement to fund expansion

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beximco Pharmaceuticals Limited

Beximco Pharmaceuticals Limited (BPL) is engaged in the manufacturing and marketing of generic pharmaceuticals formulation products, including intravenous fluids and active pharmaceutical ingredients (APIs). The Company also provides contract manufacturing services. The Company produces approximately 300 generic medicines, which are available in over 500 different presentations and the portfolio encompasses various key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology and gastrointestinal. Its product categories also include anti-infectives, musculoskeletal, oncology, respiratory, skin care, vitamins and minerals supplement, and others. The Company's products include Acifix, Femzole, Q-Rash, Tamona, Taverin, Tobasol, IcyKool Cream, Intracef, Gastalfet, Iprasol, Calorate, Gentosep and others. BPL's products are sold in domestic and international markets.

Industry

Major Drugs

Contact Info

19 Dhanmondi R/A, Road No. 7

+880.2.58611001

https://www.beximcopharma.com/

Executive Leadership

Ahmed Sohail Fasiur Rahman

Chairman of the Board

Nazmul Hassan

Chief Executive Officer, Managing Director, Director

Ahmed Salman Fazlur Rahman

Vice Chairman of the Board

Ali Nawaz

Chief Financial Officer

Rabbur Reza

Chief Operating Officer

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, BDT)

2020(E)

26.4K
Price To Earnings (TTM)
11.19
Price To Sales (TTM)
1.47
Price To Book (MRQ)
1.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
38.43
LT Debt To Equity (MRQ)
9.27
Return on Investment (TTM)
8.20
Return on Equity (TTM)
6.67

Latest News

Latest News

BRIEF-FDA approves Beximco Pharma's Methocarbamol tablets

* Beximco Pharmaceuticals Ltd says announces that it has received approval for its Methocarbamol tablets (500 mg and 750 mg) from U.S. Food and Drug Administration (U.S. FDA) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up